Biogen reported Phase 2 trial results for diranersen, a tau-targeting therapy for early Alzheimer’s, showing cognitive benefits and reduced tau biomarkers despite missing the primary endpoint. The drug slowed cognitive decline across doses, especially at the lowest dose, and was generally safe. Analysts remain cautiously optimistic about its potential and Biogen plans to continue development. Separately, Biogen completed its acquisition of Apellis Pharmaceuticals, adding two commercial nephrology drugs to its portfolio, expected to boost revenue by 2027. Biogen’s stock fell nearly 5% following the announcement.
Biogen has finalized its acquisition of Apellis Pharmaceuticals, gaining full ownership of two commercial products, EMPAVELI® and SYFOVRE®, which generated $689 million in revenue in 2025. This deal enhances Biogen's growth prospects and expands its ...
Biogen announced positive topline results from its Phase 2 CELIA study of diranersen, an investigational therapy targeting tau protein in early Alzheimer's disease. The study showed robust reductions in tau pathology and a slowing of cognitive declin...
